Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells

Neurochem Int. 2010 Nov;57(5):547-55. doi: 10.1016/j.neuint.2010.06.021. Epub 2010 Jul 6.

Abstract

Beta-amyloid (Abeta) peptide, the hallmark of Alzheimer's disease (AD), invokes a cascade of oxidative damages to neurons and eventually leads to neuronal death. In this study, salidroside (Sald), an active compound isolated from a traditional Chinese medicinal plant, Rhodiola rosea L., was investigated to assess its protective effects and the underlying mechanisms against Abeta-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Abeta(25-35)-induced neuronal toxicity was characterized by the decrease of cell viability, the release of lactate dehydrogenase (LDH), morphological alterations, neuronal DNA condensation, and the cleavage of poly(ADP-ribose) polymerase (PARP) by activated caspase-3. Pretreatment with salidroside markedly attenuated Abeta(25-35)-induced loss of cell viability and apoptosis in a dose-dependent manner. The mechanisms of salidroside protected neurons from oxidative stress included the induction of antioxidant enzymes, thioredoxin (Trx), heme oxygenase-1 (HO-1), and peroxiredoxin-I (PrxI); the downregulation of pro-apoptotic protein Bax and the upregulation of anti-apoptotic protein Bcl-X(L). Furthermore, salidroside dose-dependently restored Abeta(25-35)-induced loss of mitochondrial membrane potential (MMP) as well as suppressed the elevation of intracellular reactive oxygen species (ROS) level. It was also observed that Abeta(25-35) stimulated the phosphorylation of mitogen-activated protein (MAP) kinases, including c-Jun NH(2)-terminal kinase (JNK) and p38 MAP kinase, but not extracellular signal-regulated kinase1/2 (ERK1/2). Salidroside inhibited Abeta(25-35)-induced phosphorylation of JNK and p38 MAP kinase, but not ERK1/2. These results suggest that salidroside has protective effects against Abeta(25-35)-induced oxidative stress, which might be a potential therapeutic agent for treating or preventing neurodegenerative diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / toxicity*
  • Apoptosis / drug effects
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • DNA Primers
  • Flow Cytometry
  • Glucosides / pharmacology*
  • Heme Oxygenase-1 / biosynthesis
  • Humans
  • L-Lactate Dehydrogenase / metabolism
  • Membrane Potentials / drug effects
  • Mitochondrial Membranes / drug effects
  • Neuroprotective Agents*
  • Oxidative Stress / drug effects*
  • Peptide Fragments / antagonists & inhibitors*
  • Peptide Fragments / toxicity*
  • Phenols / pharmacology*
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Reactive Oxygen Species / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sincalide / metabolism
  • Trypan Blue
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Amyloid beta-Peptides
  • DNA Primers
  • Glucosides
  • Neuroprotective Agents
  • Peptide Fragments
  • Phenols
  • RNA, Messenger
  • Reactive Oxygen Species
  • amyloid beta-protein (25-35)
  • L-Lactate Dehydrogenase
  • Heme Oxygenase-1
  • p38 Mitogen-Activated Protein Kinases
  • Trypan Blue
  • Sincalide
  • rhodioloside